Pizotifen Explained

Verifiedfields:verified
Verifiedrevid:464208411
Iupac Name:4-(1-methyl-4-piperidylidine)-9,10-dihydro -4H-benzo-[4,5]cyclohepta[1,2]-thiophene
Width:180px
Tradename:Sandomigran, Mosegor, Litec, others
Pregnancy Au:B1
Legal Au:S4
Legal Ca:Rx-only
Legal Uk:POM
Routes Of Administration:Oral
Bioavailability:78%
Protein Bound:91%
Metabolism:Glucuronidation (main route). N-glucuronide accounts for >50% of plasma and 60–70% of urinary excreted drug
Elimination Half-Life:23 hours
Excretion:18% feces, 55% urine (both as metabolites)
Cas Number:15574-96-6
Atc Prefix:N02
Atc Suffix:CX01
Pubchem:27400
Iuphar Ligand:93
Drugbank:DB06153
Chemspiderid:25497
Unii:0BY8440V3N
Kegg:D05523
Chembl:294951
Synonyms:Pizotyline; BC-105
C:19
H:21
N:1
S:1
Smiles:s1c3c(cc1)C(\c2c(cccc2)CC3)=C4/CCN(C)CC4
Stdinchi:1S/C19H21NS/c1-20-11-8-15(9-12-20)19-16-5-3-2-4-14(16)6-7-18-17(19)10-13-21-18/h2-5,10,13H,6-9,11-12H2,1H3
Stdinchikey:FIADGNVRKBPQEU-UHFFFAOYSA-N

Pizotifen, also known as pizotyline and sold under the brand names Sandomigran and Mosegor among others, is an antimigraine agent of the tricyclic group which is used primarily as a preventative to reduce the frequency of recurrent migraine headaches.[1]

Medical uses

Migraine headaches

The main medical use for pizotifen is for the prevention of migraine and cluster headache. Pizotifen is one of a range of medications used for this purpose, other options include propranolol, topiramate, valproic acid, cyproheptadine and amitriptyline. While pizotifen is effective in adults,[2] evidence of efficacy in children is limited,[3] and its use is limited by side effects, principally drowsiness and weight gain, and it is usually not the first choice medicine for preventing migraines, instead being used as an alternative when other drugs have failed to be effective.[4] It is not effective in relieving migraine attacks once in progress.

Other uses

Pizotifen has also been reported as highly effective in a severe case of erythromelalgia, a rare neurovascular disease that is sometimes refractory to the other drugs named above.[5]

Other applications for which pizotifen may be used include as an antidepressant, or for the treatment of anxiety or social phobia.[6] [7] Animal studies also suggest that pizotyline could be used in the treatment of serotonin syndrome or MDMA overdose[8] in a similar manner to the closely related antihistamine/antiserotonin medication cyproheptadine.

Pizotifen might be useful as a hallucinogen antidote or "trip killer" in blocking the effects of serotonergic psychedelics like psilocybin.[9] It might also be useful in the treatment of MDMA overdose.

Contraindications

Caution is required in patients having closed angle glaucoma and in patients with a predisposition to urinary retention as the medication exhibits a relatively small anticholinergic effect. Dose adjustment is required in people who have chronic kidney disease. Liver injury has also been reported. Pizotifen treatment should be discontinued if there is any clinical evidence of liver dysfunction during treatment. Caution is advised in patients having a history of epilepsy.Withdrawal symptoms like depression, tremor, nausea, anxiety, malaise, dizziness, sleep disorder and weight decrease have been reported following abrupt cessation of pizotifen.[10]

Pizotifen is contraindicated in patients who suffer from hypersensitivity to any of its components, also Pizotifen is contraindicated in gastric outlet obstruction, pregnancy, angle-closure glaucoma and difficulty urinating.[11]

Adverse effects

Side effects include sedation, dry mouth, drowsiness, increased appetite and weight gain.[12] Occasionally it may cause nausea, headaches, or dizziness. In rare cases, anxiety, aggression and depression may also occur.

Pharmacology

Pharmacodynamics

Affinity (Ki, nM) Species
200–270 Human
1415 Human
770 Human
820 Human
2.0 Human
2.0–2.3 Human
8.4 Human
95 Human
Human
110 Human
74 Human
17–25 Human
3.5 Human
2.4–87 Human
64 Human
50 Human
65 Human
>10000 Human
660 Human
225 Human
390 Human
>10000 Human
>10000 Human
1.9 Human
1.4 Human
67 Human
34 Human
29 Human
130 Human
6.8 Human
121 Human
>10000 Guinea pig
6450 Rat
>10000 Human
710 Human
>10000 Human
Note: The smaller the value, the more avidly the compound binds to or activates the site. Refs: [13] [14] [15] [16] [17]

Pizotifen is a serotonin antagonist acting mainly at the 5-HT2A and 5-HT2C receptors. It also has some activity as an antihistamine as well as some anticholinergic activity.[18] The drug binds non-selectivey to many targets, including serotonin, dopamine, adrenergic, histamine, and muscarinic acetylcholine receptors.

Pizotifen is able to dose-dependently and fully antagonize the discriminative stimulus effects of the serotonin–norepinephrine–dopamine releasing agent and serotonin 5-HT2 receptor agonist MDMA in rodent drug discrimination tests. Conversely, the related drug cyproheptadine was only partially effective and clozapine was ineffective. All three of these agents, pizotifen, cyproheptadine, and clozapine act as non-selective monoamine receptor antagonists. Pizotifen also fully blocks the effects of serotonergic psychedelics, including LSD, mescaline, 5-MeO-DMT, and DOM, in drug discrimination tests.

Chemistry

Pizotifen is a tricyclic compound and is specifically a benzocycloheptene.

Close analogues of pizotifen include ketotifen and cyproheptadine, among others.

History

Pizotifen was first described in the literature by 1964.

Society and culture

Names

Pizotifen is the generic name of the drug and its and, while pizotyline is its .[19] [20] [21] Brand names of pizotifen include Sandomigran, Mosegor, and Litec, among others.

Availability

Pizotifen is available widely throughout the world, including in Europe.[22]

External links

Notes and References

  1. Stark RJ, Valenti L, Miller GC . Management of migraine in Australian general practice . The Medical Journal of Australia . 187 . 3 . 142–146 . August 2007 . 17680738 . 10.5694/j.1326-5377.2007.tb01170.x . 10357983 .
  2. Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J . 6 . A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache . PLOS ONE . 10 . 7 . e0130733 . 2015-07-14 . 26172390 . 4501738 . 10.1371/journal.pone.0130733 . free . 2015PLoSO..1030733J .
  3. Barnes N, Millman G . Do pizotifen or propranolol reduce the frequency of migraine headache? . Archives of Disease in Childhood . 89 . 7 . 684–685 . July 2004 . 15210509 . 1719986 . 10.1136/adc.2004.054668 .
  4. Pierangeli G, Cevoli S, Sancisi E, Grimaldi D, Zanigni S, Montagna P, Cortelli P . Which therapy for which patient? . Neurological Sciences . 27 . Suppl 2 . S153–S158 . May 2006 . 16688621 . 10.1007/s10072-006-0592-0 . 24217802 .
  5. Cohen JS . Erythromelalgia: new theories and new therapies . Journal of the American Academy of Dermatology . 43 . 5 Pt 1 . 841–847 . November 2000 . 11050591 . 10.1067/mjd.2000.109301 . 40807034 .
  6. Standal JE . Pizotifen as an antidepressant . Acta Psychiatrica Scandinavica . 56 . 4 . 276–279 . October 1977 . 335788 . 10.1111/j.1600-0447.1977.tb00228.x . 6445059 .
  7. Banki CM . Clinical observations with pizotifene (Sandomigran) in the treatment of nonmigrainous depressed women . Archiv für Psychiatrie und Nervenkrankheiten . 225 . 1 . 67–72 . March 1978 . 348154 . 10.1007/bf00367352 . 13510725 .
  8. Young R, Khorana N, Bondareva T, Glennon RA . Pizotyline effectively attenuates the stimulus effects of N-methyl-3,4-methylenedioxyamphetamine (MDMA) . Pharmacology, Biochemistry, and Behavior . 82 . 2 . 404–410 . October 2005 . 16253319 . 10.1016/j.pbb.2005.09.010 . 20885754 .
  9. Halman A, Kong G, Sarris J, Perkins D . Drug-drug interactions involving classic psychedelics: A systematic review . J Psychopharmacol . 38 . 1 . 3–18 . January 2024 . 37982394 . 10851641 . 10.1177/02698811231211219 .
  10. Web site: SANDOMIGRAN® pizotifen 500 micrograms coated tablets . AFT Pharmaceuticals Ltd . 21 June 2019 . Medsafe: New Zealand Medicines and Medical Devices Safety .
  11. Web site: Pizotifen . Universal reference book of medicines . Likarstwo.ru.
  12. Crowder D, Maclay WP. Pizotifen once daily in the prophylaxis of migraine: results of a multi-centre general practice study. Current Medical Research and Opinion. 1984;9(4):280-5.
  13. Web site: PDSP Database . UNC . zu . 24 November 2024.
  14. Web site: PDSP Database . UNC . zu . 24 November 2024.
  15. Web site: Liu T . BindingDB BDBM82088 CAS_15574-96-6::NSC_27400::PIZOTIFEN . BindingDB . 24 November 2024.
  16. Young R, Khorana N, Bondareva T, Glennon RA . Pizotyline effectively attenuates the stimulus effects of N-methyl-3,4-methylenedioxyamphetamine (MDMA) . Pharmacol Biochem Behav . 82 . 2 . 404–410 . October 2005 . 16253319 . 10.1016/j.pbb.2005.09.010 .
  17. Moritomo A, Yamada H, Watanabe T, Itahana H, Akuzawa S, Okada M, Ohta M . Synthesis and structure-activity relationships of new carbonyl guanidine derivatives as novel dual 5-HT2B and 5-HT7 receptor antagonists . Bioorg Med Chem . 21 . 24 . 7841–7852 . December 2013 . 24189186 . 10.1016/j.bmc.2013.10.010 .
  18. Dixon AK, Hill RC, Roemer D, Scholtysik G . Pharmacological properties of 4(1-methyl-4-piperidylidine)-9,10-dihydro-4H-benzo-[4,5]cyclohepta[1,2]-thiophene hydrogen maleate (pizotifen) . Arzneimittel-Forschung . 27 . 10 . 1968–1979 . 1977 . 411500 .
  19. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies . Springer US . 2014 . 978-1-4757-2085-3 . 24 November 2024 . 1002.
  20. Book: Schweizerischer Apotheker-Verein . Index Nominum: International Drug Directory . Medpharm Scientific Publishers . Index Nominum: International Drug Directory . 2004 . 978-3-88763-101-7 . 24 November 2024 . 992.
  21. Book: Morton IK, Hall JM . Concise Dictionary of Pharmacological Agents: Properties and Synonyms . Springer Netherlands . 2012 . 978-94-011-4439-1 . 24 November 2024 . 225.
  22. Web site: Pizotifen (International database) . Drugs.com . 3 November 2024 . 24 November 2024.